Susan Suchdev - Klaria Pharma Chief Officer
| KLAR Stock | SEK 0.36 0.04 10.00% |
Executive
Ms. Susan Suchdev serves as Chief Operating Officer at Klaria Pharma Holding AB . She holds MS, Karolinska Institute and Stockholm University, Nutrition and Clinical Development. She has previously been Head Nordic Reg. Affairs, Nestle Country Manager, IRW Unit Manager, TFS Clinical Research, Pfizer AB.
| Age | 51 |
| Phone | 46 84 46 42 99 |
| Web | https://www.klaria.com |
Klaria Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8766) %, meaning that it generated substantial loss on money invested by shareholders. Klaria Pharma's management efficiency ratios could be used to measure how well Klaria Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Thomas Areschoug | Xintela AB | 51 | |
| Monica Wallter | Lidds AB | 67 | |
Management Performance
| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 |
Klaria Pharma Holding Leadership Team
Elected by the shareholders, the Klaria Pharma's board of directors comprises two types of representatives: Klaria Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Klaria. The board's role is to monitor Klaria Pharma's management team and ensure that shareholders' interests are well served. Klaria Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Klaria Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hans MD, Chief Officer | ||
| Hans Richter, Chief Consultative | ||
| Susan Suchdev, Chief Officer | ||
| Fredrik Hubinette, Chairman CTO | ||
| Marc Willuhn, Manufacturing Chemistry | ||
| Scott Boyer, Chief Director | ||
| Jesper Wiklund, Chief Officer |
Klaria Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Klaria Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.48) % | |||
| Current Valuation | 88.14 M | |||
| Shares Outstanding | 63.1 M | |||
| Shares Owned By Insiders | 10.73 % | |||
| Shares Owned By Institutions | 9.75 % | |||
| Price To Earning | (18.43) X | |||
| Price To Book | 1.42 X | |||
| Price To Sales | 8.00 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Klaria Stock Analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.